Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways
Dan Zhao, Yu Liu, Fengchao Yi, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115698-115698
Closed Access | Times Cited: 13

Showing 13 citing articles:

Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions
Yanguo Shang, Shengnan Fu, Qingjing Hao, et al.
Bioorganic Chemistry (2024) Vol. 144, pp. 107092-107092
Closed Access | Times Cited: 9
Design, synthesis and biological evaluation of pyrrolopyrimidine urea derivatives as novel KRASG12C inhibitors for the treatment of cancer
Yanguo Shang, M. Pang, Shengnan Fu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117391-117391
Closed Access | Times Cited: 1
Design, Synthesis and Biological Evaluation of Pyrrolopyrimidine Urea Derivatives as Novel Krasg12c Inhibitors for the Treatment of Cancer
Yongfeng Shang, Shengnan Fu, M. Pang, et al.
(2025)
Closed Access
Synthetic Approaches to Piperazine-Containing Drugs Approved by FDA in the Period of 2011–2023
Maria Novella Romanelli, Laura Braconi, Alessio Gabellini, et al.
Molecules (2023) Vol. 29, Iss. 1, pp. 68-68
Open Access | Times Cited: 12
Sotorasib dosing and incremental cost ineffectiveness — implications and lessons for stakeholders
Garth W. Strohbehn, Mark J. Ratain
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 5, pp. 331-332
Closed Access | Times Cited: 4
Structure-activity relationships of middle-size cyclic peptides, KRAS inhibitors derived from an mRNA display
Mirai Kage, Ryuji Hayashi, Atsushi Matsuo, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 110, pp. 117830-117830
Closed Access | Times Cited: 3
KRAS depletion suppresses ferroptosis and affects Hippo pathway in cataract
Hongda Jiang, Yinggui Yu, Yu Yan
General Physiology and Biophysics (2024) Vol. 43, Iss. 03, pp. 243-253
Open Access | Times Cited: 2
DNA encoded peptide library for SARS-CoV-2 3CL protease covalent inhibitor discovery and profiling
Yuyu Xing, Huiya Zhang, Yanhui Wang, et al.
RSC Chemical Biology (2024) Vol. 5, Iss. 7, pp. 691-702
Open Access | Times Cited: 2
Redefining Therapeutic Approaches in Colorectal Cancer: Targeting Molecular Pathways and Overcoming Resistance
Simona Gabriela Duta-Ion, Ioana Ruxandra Juganaru, Iulian Andrei Hotinceanu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 23, pp. 12507-12507
Open Access | Times Cited: 1
Advances and challenges in RAS signaling targeted therapy in leukemia
Yu Chen, Zhengfeng Yin, Kenneth D. Westover, et al.
Molecular Cancer Therapeutics (2024) Vol. 24, Iss. 1, pp. 33-46
Open Access | Times Cited: 1
Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers
Jimi Kim
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 23, pp. 16933-16933
Open Access | Times Cited: 3
Discovery of RMC-6291, a potent, orally bioavailable, covalent RAS(ON) G12C selective inhibitor
James Cregg, Kristóf Póta, Adrian L. Gill, et al.
Elsevier eBooks (2024), pp. 277-308
Closed Access
Targeted Combination Therapies: A New Frontier in the Treatment of TP53 and KRAS Mutation-Associated Cancers
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2023) Vol. 15, Iss. 1, pp. 15-16
Closed Access | Times Cited: 1
Page 1

Scroll to top